Interrelations Between Arterial Stiffness, Target Organ Damage, and Cardiovascular Disease Outcomes

Ramachandran S. Vasan, MD; Meghan I. Short, PhD; Teemu J. Niiranen, MD; Vanessa Xanthakis, PhD; Charles DeCarli, MD; Susan Cheng, MD; Sudha Seshadri, MD; Gary F. Mitchell, MD

Background—Excess transmission of pressure pulsatility caused by increased arterial stiffness may incur microcirculatory damage in end organs (target organ damage [TOD]) and, in turn, elevate risk for cardiovascular disease (CVD) events.

Methods and Results—We related arterial stiffness measures (carotid-femoral pulse wave velocity, mean arterial pressure, central pulse pressure) to the prevalence and incidence of TOD (defined as albuminuria and/or echocardiographic left ventricular hypertrophy) in up to 6203 Framingham Study participants (mean age 50±15 years, 54% women). We then related presence of TOD to incident CVD in multivariable Cox regression models without and with adjustment for arterial stiffness measures. Cross-sectionally, greater arterial stiffness was associated with a higher prevalence of TOD (adjusted odds ratios ranging from 1.23 to 1.54 per SD increment in arterial stiffness measure, \( P < 0.01 \)). Prospectively, increased carotid-femoral pulse wave velocity was associated with incident albuminuria (odds ratio per SD 1.28, 95% CI, 1.02–1.61; \( P < 0.05 \)), whereas higher mean arterial pressure and central pulse pressure were associated with incident left ventricular hypertrophy (odds ratio per SD 1.37 and 1.45, respectively; \( P < 0.01 \)). On follow-up, 297 of 5803 participants experienced a first CVD event. Presence of TOD was associated with a 33% greater hazard of incident CVD (95% CI, 0.77–77%; \( P < 0.05 \)), which was attenuated upon adjustment for baseline arterial stiffness measures by 5–21%.

Conclusions—Elevated arterial stiffness is associated with presence of TOD and may partially mediate the relations of TOD with incident CVD. Our observations in a large community-based sample suggest that mitigating arterial stiffness may lower the burden of TOD and, in turn, clinical CVD. (J Am Heart Assoc. 2019;8:e012141. DOI: 10.1161/JAHA.119.012141.)

Key Words: arterial stiffness • cardiovascular disease • epidemiology • pulse wave velocity • target organ damage

Numerous studies have demonstrated a strong association between high blood pressure (BP) and structural and functional changes in end organs (heart, brain, eyes, and kidneys), which are referred to as target organ damage (TOD). Evidence of TOD is frequently seen in individuals with more severe or long-standing elevations in BP. With wider use of imaging and screening tests (which are also increasing in sensitivity), TOD is becoming more apparent among asymptomatic individuals with milder forms of BP elevation. Important, any presence of TOD confers significant risk for developing overt cardiovascular disease (CVD), and there is evidence to suggest that regression of TOD with BP lowering may mitigate this risk. Thus, recent BP guidelines recommend screening for TOD in individuals with high BP. Such screening is accomplished typically by evaluating the retinal microcirculation, a spot urine specimen for presence of albuminuria, and assessment for ECG or echocardiographic evidence of left ventricular (LV) hypertrophy (LVH).

In conjunction with the clinical guidelines’ emphasis on TOD screening, an emerging body of literature suggests that TOD may be caused by end-organ microcirculatory injury caused by excess transmission of pressure pulsatility from arterial stiffening, above and beyond the effects of peripheral BP elevation. To date, however, a comprehensive understanding of the interrelations between central vascular...

From the National Heart, Lung, and Blood Institute’s and Boston University’s Framingham Heart Study, Framingham, MA (R.S.V., T.I.N., V.X., S.C., S.S.); Section of Preventive Medicine, Department of Medicine (R.S.V., V.X.), and Section of Cardiology, Department of Medicine (R.S.V.), Boston University School of Medicine, Boston, MA; Department of Epidemiology (R.S.V.) and Department of Biostatistics (M.I.S., V.X.), Boston University School of Public Health, Boston, MA; Department of Medicine, Turku University Hospital and University of Turku, Finland (T.J.N.); Department of Public Health Solutions, National Institute for Health and Welfare, Turku, Finland (T.J.N.); University of California, Davis, CA (C.D.); Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (S.C.); Biggs Institute for Alzheimer’s Disease, University of Texas Health Sciences Center at San Antonio, TX (S.S., M.I.S.); Cardiovascular Engineering, Inc., Norwood, MA (G.F.M.).

Correspondence to: Ramachandran S. Vasan, MD, The Framingham Heart Study, 73 Mt. Wayte Avenue, Suite 2, Framingham, MA 01702. E-mail: vasan@bu.edu

Received April 2, 2019; accepted June 3, 2019.

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

DOI: 10.1161/JAHA.119.012141
Clinical Perspective

What Is New?

- We related arterial stiffness measures to the prevalence and incidence of target organ damage (defined as albuminuria and/or echocardiographic left ventricular hypertrophy), and then related the presence of target organ damage to incident cardiovascular disease in analyses without and with adjustment for arterial stiffness measures.
- Greater arterial stiffness was associated with a greater prevalence and incidence of target organ damage, and the latter, in turn, was associated with a greater hazard of incident cardiovascular disease events.

What Are the Clinical Implications?

- Elevated arterial stiffness promotes target organ damage and partially mediates the relations of the latter to incident cardiovascular disease, suggesting that mitigating arterial stiffness may lower the burden of both target organ damage and clinical cardiovascular disease.

hemodynamics, hypertensive TOD, and CVD outcomes has been lacking. Most prior studies have assessed the relations between peripheral (rather than central) BP and TOD in a single end organ, often using a cross-sectional study design.13–19 Few studies have evaluated the relative contributions of steady state and pulsatile pressure (ie, mean arterial pressure [MAP] and pulse pressure [PP], respectively) and aortic stiffness (as reflected by carotid-femoral pulse wave velocity [CFPWV]) to the occurrence of TOD assessed across multiple end organs and, thereafter, progression to CVD incidence.

We hypothesized that elevated arterial stiffness would be associated with TOD cross-sectionally and with the incidence of TOD prospectively. We postulated that the association of arterial stiffness measures with CVD incidence would be mediated partly via the impact of steady state and pulsatile pressure hemodynamic components on TOD. We also posited that the association of TOD with CVD incidence would be partially attenuated when accounting for concomitant arterial stiffness (Figure 1). We tested these hypotheses in a community-based sample with contemporaneous assessments of central hemodynamic and arterial stiffness measures and TOD.

Methods

Study Sample

The design and selection criteria of FHS (Framingham Heart Study) cohorts have been previously described. Beginning in 1948, approximately two thirds of the households in Framingham, MA, were enrolled in the Original Cohort (n=5209).20 Their offspring (and their spouses) and the children of the offspring were enrolled in the Offspring Cohort and the Generation 3 Cohort in 1971 and 2002, respectively, as detailed elsewhere.21,22 In addition, 2 Omni cohorts (combined n=916) were recruited in 1994 and 2003 to reflect the increasingly diverse population of Framingham. These cohorts specifically targeted residents of Hispanic, Asian, Indian, African American, Pacific Islander, and Native American descent.23 The study protocol was approved by the institutional review board at the Boston Medical Center and all participants provided written informed consent. All data and materials have been made publicly available at the National Heart, Lung, and Blood Institute’s data repository BioLINCC.24,25

For the current investigation (Figure 2), we considered 7927 FHS participants who took part in Offspring Cohort examination 8 (2005–2008), Third Generation Cohort examination 1 (2002–2005), First Omni Cohort examination 3 (2007–2008), Second Omni Cohort examination 1 (2003–2005), or New Offspring Spouse examination 1 (2003–2005).

![Figure 1](image.png)

**Figure 1.** Conceptual framework for analyses. “a” refers to multivariable-adjusted regression coefficient relating arterial stiffness measure to presence vs absence of target organ damage (TOD); it is the direct effect of arterial stiffness on TOD. “b” refers to multivariable-adjusted regression coefficient relating TOD to the incidence of cardiovascular disease (CVD) (without arterial stiffness measures in the model); it is the overall effect of TOD on CVD corrected for confounders. “c” refers to multivariable-adjusted regression coefficient relating arterial stiffness measures to the incidence of CVD; it is the direct effect of TOD on CVD incidence. “c’” refers to multivariable-adjusted regression coefficient relating arterial stiffness measures to the incidence of CVD with additional adjustment for presence of TOD at baseline; it is the direct effect of arterial stiffness on CVD incidence.
These examinations are referred to as the baseline for the present analyses. Overall, 6203 individuals had data available for covariates, central hemodynamics, LVH, and albuminuria, and were included in analyses relating central hemodynamics with albuminuria and LVH (Figure 2). Of these participants, 3144 underwent brain magnetic resonance imaging (MRI) and were included in analyses relating hemodynamic measures with all types of organ damage (Figure 2). In total, 5803 individuals without history of CVD had no missing data for covariates, albuminuria, LVH, or central hemodynamics and were included in analyses on the association of albuminuria and LVH with incident cardiovascular outcomes (Figure 2). A subsample of 4215 individuals free of albuminuria (Offspring and Third Generation Cohort participants) and 1111 free of echocardiographic LVH (Offspring Cohort) attended the subsequent examination at which incidence of albuminuria and echocardiographic LVH was reassessed.

Hemodynamic Assessment With Arterial Tonometry
Supine brachial systolic and diastolic BPs were obtained using an auscultatory device. Vascular stiffness was assessed using arterial applanation tonometry as previously described. Briefly, arterial tonometry with simultaneous ECG recordings was performed on the brachial, femoral, and carotid arteries on the right side of the body of participants. Transit distances for arterial pulse waves were assessed by body surface measurements from the suprasternal notch to the pulse-recording sites. MAP was derived from integration of the brachial waveform, which was calibrated by using systolic and diastolic auscultatory BP at the time of tonometry. Diastolic BP and integrated MAP were used to calibrate carotid pressure tracings from which central aortic pressure was calculated. Details of signal analyses and data processing have been published. In our experience at FHS, MAP derived from applanation tonometry of the brachial artery is very highly correlated with that derived from a similarly calibrated and integrated signal-averaged oscillometric brachial pressure waveform (r exceeds 0.96).

For the present investigation, we assessed 3 primary measures of arterial stiffness and central hemodynamics: (1) CFPWV, the current reference standard for aortic stiffness; (2) central PP (CPP), ie, the BP amplitude in the proximal aorta; and (3) central MAP, reflecting steady state pressure in the large arteries.

Target Organ Damage
Transthoracic echocardiography with Doppler color flow imaging was performed at the index FHS examinations using a standardized protocol. All echocardiograms were evaluated by an experienced sonographer or cardiologist and measured using a standardized reading protocol. Cardiac dimensions were quantified using digital images and the leading-edge technique as recommended by the American Society of Echocardiography. LV mass was calculated according to American Society of Echocardiography guidelines. We defined LVH as LV mass index >95 g/m² and >115 g/m² for women and men, respectively. A subsequent measure of
Table 1. Characteristics of Study Participants (According to Different Samples*)

| Characteristic | Sample for Cross-Sectional Analyses | Sample for Outcome Analyses |
|---------------|------------------------------------|-----------------------------|
|               | Larger Sample (Sample 1)           | Sample With Brain MRI Measures (Sample 2) | Incident TOD |
|               |                                    | Incident Microalbuminuria (Sample 3) | Incident LVH (Sample 4) | Incident CVD (Sample 5) |
| No.           | 6203                               | 3144                         | 4215 | 1111 | 5803 |
| Age, y        | 50±15                              | 50±15                        | 48±14 | 63±8 | 49±15 |
| Women, No. (%)| 3340 (53.8)                        | 1683 (53.5)                  | 2271 (53.9) | 633 (57.0) | 3176 (54.7) |
| Systolic BP, mm Hg | 121±16                           | 120±16                       | 119±15 | 125±16 | 120±16 |
| Diastolic BP, mm Hg | 74±10                            | 74±10                        | 75±9  | 74±9  | 75±10 |
| Hypertension, No. (%) | 1966 (31.7)              | 915 (29.1)                   | 1058 (25.1) | 525 (47.3) | 1662 (28.6) |
| Duration, median (Q1–Q3), y† | 10 (6–18)           | 10 (6–18)                    | 10 (2–18) | 10 (2–18) | 10 (2–18) |
| BP-lowering medication, No. (%) | 1452 (23.4)           | 667 (21.2)                   | 731 (17.3) | 421 (37.9) | 1180 (20.3) |
| Duration, median (Q1–Q3), y† | 6 (2–14)             | 6 (2–14)                     | 6 (2–10) | 6 (2–10) | 6 (2–10) |
| Central PP, mm Hg | 58±19                             | 57±19                        | 55±16 | 65±19 | 57±18 |
| MAP, mm Hg    | 93±12                             | 92±12                        | 91±11 | 96±11 | 92±12 |
| CFPWV, m/s    | 8.3±3.0                           | 8.2±2.8                      | 7.8±2.3 | 9.5±2.8 | 8.1±2.7 |
| Heart rate, beats per min | 60±9                             | 59±9                         | 60±9  | 59±9  | 60±9  |
| BMI, kg/m²    | 26.9±5.0                          | 26.8±4.8                     | 26.7±4.9 | 27.5±4.7 | 26.8±4.9 |
| Prevalent CVD, No. (%) | 400 (6.4)             | 142 (4.5)                    | 141 (3.3) | 95 (8.6) | . . . |
| Smoking, No. (%) | 779 (12.6)            | 331 (10.5)                   | 513 (12.2) | 85 (7.7) | 735 (12.7) |
| Diabetes mellitus, No. (%) | 382 (6.2)          | 168 (5.3)                    | 162 (3.8) | 85 (7.7) | 283 (4.9) |
| Duration, median (Q1–Q3), y† | 6 (2–14)             | 6 (2–14)                     | 6 (2–10) | 6 (2–10) | 6 (2–10) |
| Treatment for diabetes mellitus, No. (%) | 255 (4.1)         | 108 (3.4)                    | 95 (2.3) | 52 (4.7) | 180 (3.1) |
| Duration, median (Q1–Q3), y† | 6 (2–10)             | 2 (2–10)                     | 2 (2–8)  | 2 (2–8) | 2 (2–10) |
| Glycated hemoglobin, % | 5.7±0.6               | 5.7±0.5                      | 5.6±0.5 | 5.6±0.5 | 5.7±0.6 |
| TC/HDL cholesterol ratio | 3.6±1.3                | 3.6±1.3                      | 3.6 ±1.3 | 3.5±1.0 | 3.6±1.3 |
| Triglycerides, mg/dL | 114±80               | 111±77                       | 111±78 | 111±61 | 113±80 |
| Lipid medication, No. (%) | 1264 (20.4)        | 603 (19.2)                   | 675 (16.0) | 392 (35.3) | 979 (16.9) |
| eGFR, ml/min per 1.73 m² | 94±19                | 94±18                        | 96±17  | 81±14 | 95±18 |
| Cohort, No. (%) |                                    |                              |        |       |       |
| Offspring     | 2308 (37.2)                     | 1269 (40.4)                  | 1414 (33.5) | 1111 (100.0) | 1983 (34.2) |
| Third Generation | 3657 (59.0)                | 1875 (59.6)                  | 2801 (66.5) | 0 (0.0) | 3614 (62.3) |
| Omni 1        | 238 (3.8)                       | 0 (0.0)                      | 0 (0.0)  | 0 (0.0) | 206 (3.5) |

Summary statistics are mean±SD unless otherwise specified. BMI indicates body mass index; BP, blood pressure; CFPWV, carotid-femoral pulse wave velocity; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; LVH, left ventricular hypertrophy; MAP, mean arterial pressure; MRI, magnetic resonance imaging; PP, pulse pressure; Q, quartile; TC/HDL, total cholesterol/high-density lipoprotein cholesterol; TOD, target organ damage.

* See Figure 2 for derivation of samples.
† Among those with the relevant condition. Duration was measured in the Offspring Cohort only and was estimated based on number of examinations attended with the condition present.
‡ Not measured in Generation 3.

LV mass (obtained using the same imaging and measurement protocol) was available in the Offspring Cohort at their ninth examination cycle (2011–2014).

Urinary albumin-creatinine ratio (UACR) was measured from spot morning urine samples obtained from participants during their FHS examinations. UACR is a reliable measure of urinary albumin excretion, and is highly correlated with albumin excretion rates obtained from 24-hour collection.30 Urinary albumin concentration was measured using an immunoturbidimetry assay. Urinary creatinine was assessed...
using a modified Jaffé method. Albuminuria was defined using the sex-specific cut points of UACR ≥17 mg/g (men) or ≥25 mg/g (women). Follow-up measurements of UACR were available at the subsequent examination in a majority of the participants (see Figure 2).

Brain MRI was performed on a subset of FHS participants using methods that have been previously described. The MRI markers of TOD were covert brain infarcts (CBIs) (ie, in the absence of a clinical stroke event or transient ischemic attack), and large white matter hyperintensities (WMHs). MRI acquisition, measurement techniques, and interrater reliability have been previously described. Operators blinded to participants’ demographic, clinical, and biomarker data rated the images of interest. We determined the volume of WMH according to previously published methods, and defined extensive WMH where the natural log of the ratio of WMH volume to total cranial volume was >1 SD above the age-adjusted mean value for this cohort. We manually characterized CBIs based on their size, location, and imaging characteristics, as previously described.

**Clinical Cardiovascular Outcomes**

All FHS participants are under continuous surveillance for the incidence of CVD events and death. We obtained medical records for all hospitalizations and physician visits related to new-onset CVD during follow-up, which were reviewed by an adjudication panel consisting of 3 physician investigators using standardized criteria. For the present investigation, CVD was comprised of a composite of cardiovascular death, fatal or nonfatal myocardial infarction, stroke, angina pectoris, unstable angina (prolonged ischemic episode with documented reversible ST-segment changes), transient ischemic attack, heart failure, and intermittent claudication. Criteria for these CVD events have been previously described.

**Statistical Analysis**

The 5 different study samples (Figure 2) contributed to different sets of analyses. We used the largest sample (sample 1, N=6203) for cross-sectional analyses relating each of the 3 arterial stiffness/hemodynamic measures (separate analyses for each measure) to the presence of TOD (echocardiographic LVH and albuminuria, modeled individually and conjointly) (Figure 1; a). A smaller sample (sample 2, N=3144) was used for relating arterial stiffness measures to prevalence of TOD as evidenced by brain MRI (CBI and WMH, modeled individually and conjointly with echocardiographic LVH and albuminuria). We used multivariable logistic regression to evaluate the cross-sectional associations, with
CFPWV, CPP, and MAP as the independent variables and TOD (albuminuria, LVH, CBI, and WMH) as the dependent variables, and fitting separate models for each combination of arterial stiffness measure and TOD. We also fit a model with presence versus absence of any TOD as the binary dependent variable. Regression models adjusted for age, sex, body mass index, diabetes mellitus, antihypertensive treatment, smoking, prevalent cardiovascular disease, total cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, lipid-lowering medications, heart rate, estimated glomerular filtration rate. Arterial stiffness measures are not adjusted for one another unless indicated otherwise. See Figure 2 for derivation of samples. BP indicates blood pressure; CBIs, covert brain infarcts; CFPWV, carotid-femoral pulse wave velocity; LVH, left ventricular hypertrophy; MAP, mean arterial pressure; PP, pulse pressure; TOD, target organ damage; WMH, large white matter hyperintensity on brain magnetic resonance imaging.

In secondary analyses, we modeled LV mass and UACR as continuous variables using linear regression models adjusting for the covariates noted above. For all analyses, CFPWV was transformed by taking the inverse to reduce skewness of the distribution of the data, and multiplied by $1000$ to retain the directionality of the variable, in which larger values are associated with worse outcomes.

In prospective analyses, we related each arterial stiffness measure individually to the incidence of TOD on follow-up among individuals free of TOD at baseline using multivariable logistic regression models. Separate analyses were performed for incident albuminuria (sample 3, N=4215 participants free of baseline albuminuria who attended the next follow-up visit).

### Table 3. Cross-Sectional Relations of Pulsatile and Steady State Hemodynamics (Arterial Stiffness Measures) to TOD: Results Adjusting for Brachial BP Variables

| Characteristic                        | Sample 1                                      | Sample 2                                      |
|---------------------------------------|------------------------------------------------|------------------------------------------------|
|                                       | ≥1 Form of TOD (Albuminuria, LVH)  | ≥1 Form of TOD (Albuminuria, LVH, CBIs, or WMH) |
| No. of participants                   | 6203                                           | 3144                                           |
| No. with TOD                          | 960                                            | 907                                            |
| Arterial stiffness measure            | OR (95% CI) for TOD                            |                                                |
| Central PP                            | 1.44 (1.33–1.56)*                             | 1.32 (1.20–1.46)*                             |
| Central MAP                           | 1.36 (1.25–1.48)*                             | 1.38 (1.26–1.52)*                             |
| Adjusted for brachial systolic BP     | 1.17 (1.05–1.30)                               | 1.23 (1.08–1.39)                               |
| Adjusted for brachial diastolic BP    | 1.53 (1.38–1.68)*                             | 1.46 (1.30–1.64)*                             |
| CFPWV                                 | 1.39 (1.22–1.57)*                             | 1.31 (1.14–1.51)*                             |
| Adjusted for central PP               | 1.17 (1.02–1.33)                              | 1.18 (1.02–1.37)                              |
| Adjusted for brachial PP              | 1.19 (1.05–1.35)                              | 1.19 (1.03–1.38)                              |
| Adjusted for brachial systolic BP     | 1.16 (1.01–1.33)                               | 1.12 (0.96–1.30)                              |
| Adjusted for brachial diastolic BP    | 1.38 (1.21–1.57)*                             | 1.27 (1.10–1.46)                              |

Odds ratios (ORs) are reported for 1-SD increase in arterial stiffness measure and are adjusted for age, sex, body mass index, diabetes mellitus, antihypertensive treatment, smoking, prevalent cardiovascular disease, total cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, lipid-lowering medications, heart rate, estimated glomerular filtration rate. Arterial stiffness measures are not adjusted for one another unless indicated otherwise. See Figure 2 for derivation of samples. BP indicates blood pressure; CBIs, covert brain infarcts; CFPWV, carotid-femoral pulse wave velocity; LVH, left ventricular hypertrophy; MAP, mean arterial pressure; PP, pulse pressure; TOD, target organ damage; WMH, large white matter hyperintensity on brain magnetic resonance imaging.

*P<0.001; †P<0.01; ‡P<0.05.

### Figure 3. Prevalence of target organ damage (albuminuria and left ventricular hypertrophy [LVH]) according to tertile of arterial stiffness measures. P values indicate tests of trend across tertiles of arterial stiffness measure (A, central pulse pressure [CPP]; B, mean arterial pressure [MAP]; C, carotid-femoral pulse wave velocity [CFPWV]).

DOI: 10.1161/JAHA.119.012141  Journal of the American Heart Association 6
follow-up examination) and incident echocardiographic LVH (sample 4, N=1111 individuals free of LVH at baseline who had repeated echocardiographic examination at the next follow-up examination). Models were adjusted for the covariates listed above.

In additional prospective analyses, we related the presence of TOD at the baseline examination to the incidence of CVD in 5803 individuals without prevalent CVD (sample 5, N=5803) using Cox regression models after confirming that the assumption of proportionality of hazards was met. The models were adjusted for the aforementioned covariates besides prevalent CVD. In addition, to describe how associations between TOD and incident CVD may be mediated by arterial stiffness measures, we evaluated associations of TOD with CVD after adjusting for CFPWV, CPP, and MAP (in separate models) to assess the extent of attenuation of associations (Figure 1; b/b').

Since the relations of TOD and arterial stiffness may be bidirectional, we performed additional analyses in which we related the 3 arterial stiffness measures individually to CVD incidence (sample 5, N=5803) using multivariable-adjusted Cox regression models. We evaluated these relations with and without adjusting for presence versus absence of TOD (Figure 1; c/c').

We considered a 2-sided P<0.05 statistically significant across all analyses. The variance in all models was adjusted for familial structure, using generalized estimating equations for linear and logistic models, and the robust sandwich estimator for Cox proportional hazards models. We performed statistical analyses using SAS software version 9.4 (SAS Institute, Inc). Dr Vasan had access to all of the study data and takes responsibility for its integrity and that of the data analyses.

Table 1 (samples are as shown in Figure 2). Arterial stiffness measures were correlated with each other: age- and sex-adjusted Pearson correlation coefficients of MAP were 0.50 and 0.47 in relation to CPP and PWV, respectively, and 0.28 between CPP and PWV (all P<0.0001).

In a sample of 6203 individuals, 476 (7.7%) and 602 (9.7%) had albuminuria and echocardiographic LVH, respectively, whereas 960 participants (15.5%) had ≥1 form of TOD (Table 2). The prevalence of TOD rose across tertiles of all 3 arterial stiffness measures (Figure 3). In cross-sectional analyses, CPP, MAP, and PWV were all positively related to arterial stiffness measures or across type of TOD (P<0.01 for all, Table 2). In additional analyses limited to the Offspring Cohort (in which data on the durations of hypertension and diabetes mellitus were available; see Table 1), we adjusted for the duration of both hypertension and diabetes mellitus in multivariable models. In these additional analyses, the association of arterial stiffness measures with the prevalence of TOD was maintained (Table 2, lower half). The associations of PWV with prevalent

Table 4. Relations of Pulsatile and Steady State Hemodynamics (Arterial Stiffness Measures) and UACR and LV Mass Modeled as Continuous Variables in Sample 1

| Arterial Stiffness Measure | Log UACR Beta (SE) | P Value | Log LVMI Beta (SE) | P Value |
|----------------------------|--------------------|---------|--------------------|---------|
| Central PP                 | 0.134 (0.015)      | <0.0001 | 0.037 (0.003)      | <0.0001 |
| Central MAP                | 0.071 (0.013)      | <0.0001 | 0.026 (0.003)      | <0.0001 |
| CFPWV                      | 0.144 (0.019)      | <0.0001 | 0.018 (0.004)      | <0.0001 |

Beta coefficients are per 1-SD increase in arterial stiffness measure. Log urine albumin/creatinine ratio (UACR) and log left ventricular (LV) mass index (LVMI) are the dependent variables modeled as continuous variables. Models adjusted for the following covariates: age, sex, body mass index, diabetes mellitus, antihypertensive treatment, smoking, prevalent cardiovascular disease, total cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, lipid-lowering medications, heart rate, estimate glomerular filtration rate. CFPWV indicates carotid-femoral pulse wave velocity; MAP, mean arterial pressure; PP, pulse pressure; SE, standard error.

Results

The baseline characteristics of all participants included in any analyses and in subgroups by analysis type are presented in

---

DOI: 10.1161/JAHA.119.012141

Journal of the American Heart Association 7
TOD were maintained even after additional adjustment for CPP or brachial PP (Table 3). Associations of MAP and PWV with TOD were also maintained when the corresponding regression models were adjusted for brachial systolic or diastolic BP (Table 3, lower half). In additional analyses modeling albuminuria and LV mass as continuous variables (natural logarithmically transformed to normalize their skewed distributions), these associations with arterial stiffness measures remained robust (Table 4).

In a subsample of 3144 individuals with available brain MRI data at the baseline examinations, 231 (7.3%) and 399 (12.7%) had CBI and WMH, respectively, whereas 907 participants (28.8%) had ≥1 form of TOD (Table 2). The prevalence of WMH rose across tertiles of all 3 vascular stiffness measures (Figure 4). Higher PWV was related to greater odds of prevalent CBI (P<0.05), whereas this association was borderline significant for MAP and statistically nonsignificant for CPP (Table 2). All 3 arterial stiffness measures were associated positively with prevalent WMH in multivariable-adjusted analyses (P<0.05; Table 2).

In prospective analyses, relating arterial stiffness measures to incident TOD (separate analyses for albuminuria and LVH), 224 of 4215 individuals (5.3%) developed new-onset albuminuria and 118 of 1111 participants (10.6%) developed echocardiographic LVH (Table 5). In multivariable-adjusted analyses, a 1-SD increase in transformed PWV was associated with a 28% greater odds of incident albuminuria (P<0.05), whereas 1-SD increases in MAP and CPP were associated with a 37% to 45% higher odds of incident LVH (P<0.01 for both, Table 5). The associations of PWV with incident albuminuria were maintained even after additional adjustment for CPP, brachial PP, or brachial systolic or diastolic BP (Table 5). The associations of MAP with incident albuminuria were also maintained when the corresponding regression models were adjusted for brachial diastolic BP but slightly attenuated upon adjustment for brachial systolic BP (Table 5). In analyses additionally adjusting for the durations of both hypertension and diabetes mellitus in the Offspring Cohort, the association of arterial stiffness measures with the incidence of TOD was maintained.
On follow-up (median 10.3 years, range 0.04–13.7), 297 of 5803 (5.1%) individuals free of prevalent CVD experienced a first CVD event, including 207 events in 5206 (4.0%) participants without TOD at baseline, and 90 events in 777 (11.6%) individuals with prevalent TOD, including 20 events in 68 (29.4%) participants with both forms of TOD. In multivariable models not adjusting for arterial stiffness, the presence of at least 1 form of organ damage was associated with a 33% increased risk of CVD, and the presence of 2 types of organ damage was associated with a 127% increased risk of CVD compared with the referent group without any TOD (Table 6). Additional adjustment for arterial stiffness variables attenuated these associations by 4% to 23%, with the greatest attenuation upon adjustment for CPP (Table 6). In additional analyses limited to the Offspring Cohort and adjusting for durations of hypertension and diabetes mellitus, the aforementioned associations were maintained (Table 6, lower part).

In analyses relating arterial stiffness measures to CVD incidence, a 1-SD increase in CPP was associated with a 25% greater risk of CVD, an association that was attenuated 5% upon adjustment for the presence of TOD (Table 7). Figure 5 displays the greater cumulative incidence of CVD with presence of TOD and with rising tertile-defined category of each arterial stiffness measure (P<0.01 for all).

Secondary analyses of the composite outcome of CVD or mortality yielded results essentially similar to the primary analyses (Tables 8 and 9). Presence of TOD and higher CPP were both independently associated with the composite outcome. Adjustment for arterial stiffness led to a 2% to 23% attenuation of the observed hazards ratio associated with presence of TOD. Conversely, adjustment for TOD attenuated the association of CPP with the outcome modestly.

**Discussion**

**Principal Findings**

In our large community-based sample, we investigated the associations of arterial stiffness measures with TOD and explored the relations of both sets of measures with incident CVD and mortality. Our principal findings were 3-fold. First, higher arterial stiffness was associated with increased burden of TOD both in cross-sectional and prospective analyses. These associations were consistent across the 3 arterial stiffness measures (CPP, MAP, and CFPWV) for different measures of TOD (albuminuria, LVH, and WMH) in cross-sectional analyses; however, higher CFPWV was more strongly associated with higher odds of prevalent CBI compared with the other arterial stiffness measures. In prospective analyses
of subsamples with repeated assessment of albuminuria and LVH at a follow-up examination, greater CFPWV was associated with higher odds of incident albuminuria, whereas higher CPP and MAP were associated with incident LVH. The results of these cross-sectional and prospective analyses relating arterial stiffness to prevalent and incident TOD and new-onset CVD were maintained even upon adjustment for the durations of hypertension and diabetes mellitus in analyses limited to the Offspring Cohort in which such durations could be estimated. Overall, these associations seem intuitive, given that central hemodynamic factors (reflected by MAP and CPP) impose greater ventricular afterload and directly increase LV wall stress. CFPWV, on the other hand, may better capture the downstream impact of elevated aortic stiffness on the renal microcirculation and consequent albuminuria.

Second, presence of TOD was associated with incident CVD and the composite outcome of CVD or death. Additional adjustment for arterial stiffness measures modestly attenuated these relations; this attenuation was most evident upon adjustment for CPP. Since coronary heart disease, cerebrovascular events, and heart failure are key components of incident CVD, our observations may be intuitive as these

| Table 6. Relations of TOD to the Incidence of CVD on Follow-Up |
|---------------------------------------------------------------|
| **TOD** | **No. of Participants** | **No. of Events** | **HR (95% CI)** |
|---------|-------------------------|------------------|-----------------|
|         |                         |                  | Only Covariates | Covariates+CPP | Covariates+MAP | Covariates+PWV |
| Analyses of Sample 5 |
| No. of TODs |
| 0 | 5026 | 207 | Referent | Referent | Referent | Referent |
| ≥1 | 777 | 90 | 1.33 (1.00–1.77)* | 1.26 (0.94–1.68) | 1.31 (0.98–1.74) | 1.32 (0.99–1.75) |
| % Attenuation of effect size for ≥1 TOD upon adjustment for arterial stiffness measure | 0.0 (referent) | 20.7 | 6.6 | 4.7 |
| No. of TODs |
| 0 | 5026 | 207 | Referent | Referent | Referent | Referent |
| 1 | 709 | 70 | 1.21 (0.89–1.63) | 1.17 (0.86–1.59) | 1.19 (0.88–1.62) | 1.20 (0.89–1.62) |
| 2 | 68 | 20 | 2.27 (1.39–3.69)† | 1.88 (1.12–3.16)* | 2.17 (1.31–3.59)† | 2.18 (1.33–3.58)† |
| P for trend | 0.007 | 0.04 | 0.01 | 0.01 |
| % Attenuation of effect size for TOD upon adjustment for arterial stiffness measure |
| 1 TOD | Referent | 17.7 | 5.3 | 3.8 |
| 2 TOD | Referent | 22.9 | 5.4 | 4.6 |
| Analyses with additional adjustment for duration of hypertension and diabetes mellitus (data for the Offspring Cohort only) |
| No. of TODs |
| 0 | 1557 | 135 | Referent | Referent | Referent | Referent |
| ≥1 | 425 | 73 | 1.28 (0.95–1.71) | 1.23 (0.91–1.66) | 1.27 (0.95–1.72) | 1.27 (0.95–1.71) |
| % Attenuation of effect size for ≥1 TOD upon adjustment for arterial stiffness measure | 0.0 (referent) | 14.8 | 0.4 | 1.3 |
| No. of TODs |
| 0 | 1557 | 135 | Referent | Referent | Referent | Referent |
| 1 | 377 | 55 | 1.15 (0.84–1.58) | 1.14 (0.83–1.56) | 1.15 (0.84–1.58) | 1.15 (0.84–1.57) |
| 2 | 48 | 18 | 2.14 (1.27–3.61)† | 1.85 (1.07–3.21)* | 2.17 (1.27–3.69)† | 2.13 (1.26–3.61)† |
| P for trend | 0.02 | 0.06 | 0.02 | 0.02 |
| % Attenuation of effect size for TOD upon adjustment for arterial stiffness measure |
| 1 TOD | Referent | 8.6 | No attenuation | 0.3 |
| 2 TOD | Referent | 19.4 | No attenuation | 0.8 |

Hazard ratios (HRs) are adjusted for age, sex, body mass index, diabetes mellitus, antihypertensive treatment, smoking, total cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, lipid-lowering medications, heart rate, and estimated glomerular filtration rate. Duration of hypertension and diabetes mellitus was measured in the Offspring Cohort only and was estimated based on number of examinations attended with the condition present. CPP indicates central pulse pressure; CVD, cardiovascular disease; MAP, mean arterial pressure; PWV, pulse wave velocity; TOD, target organ damage.

*P<0.05; †P<0.01.
events are more directly related to central hemodynamic factors. Overall, these observations are consistent with the notion that one key component of the vascular risk posed by the presence of TOD may be attributable to the association of TOD with elevated arterial stiffness.

Third, increased CPP was associated with greater incidence of CVD and the composite outcome of CVD or death. Additional adjustment for presence of TOD only modestly attenuated this association, confirming the conjoint and independent impacts of arterial stiffness and TOD on adverse outcomes. These observations suggest that only a modest component of the vascular risk posed by elevated CPP may be mediated by the association of the latter with presence of TOD, itself an antecedent of CVD.

Comparison With the Published Literature and Mechanisms

As noted earlier, several reports have related the presence of TOD to the incidence of CVD. A parallel set of investigations, including from our group, have underscored the relations of elevated arterial stiffness to CVD incidence. On the other hand, studies relating arterial stiffness or pulsatile hemodynamics to TOD have been predominantly cross-sectional and

### Table 7. Relations of Arterial Stiffness Measures to CVD Incidence

| Arterial Stiffness Measure | Model Adjusted for Covariates But Not for TOD | Model Adjusted for Covariates+ Presence of TOD (Yes/No) |
|----------------------------|---------------------------------------------|--------------------------------------------------------|
|                            | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Central PP                 | 1.25 (1.12–1.40) | <0.0001 | 1.24 (1.10–1.39) | 0.0003 |
| % Attenuation upon adjustment for TOD | Referent | | Referent | |
| Central MAP                | 1.10 (0.97–1.23) | 0.14 | 1.08 (0.96–1.22) | 0.21 |
| CFPWV                      | 1.15 (0.95–1.39) | 0.16 | 1.13 (0.94–1.37) | 0.21 |
| No. of events/No. at risk  | 297/5803 | | | |

Hazard ratios (HRs) correspond to 1-SD increase in the arterial stiffness measure and are adjusted for age, sex, body mass index, diabetes mellitus, antihypertensive treatment, smoking, total cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, lipid-lowering medications, heart rate, and estimated glomerular filtration rate. CFPWV indicates carotid-femoral pulse wave velocity; CVD, cardiovascular disease; MAP, mean arterial pressure; PP, pulse pressure; TOD, target organ damage.

### Table 8. Relations of TOD to the Incidence of CVD and Mortality (Composite Outcome)

| TOD | No. of Participants | No. of Events | HR (95% CI) |
|-----|---------------------|--------------|-------------|
|     | Models Adjusted For |              |             |
|     | Only Covariates     | Covariates+CPP | Covariates+MAP | Covariates+PWV |
| No. of TODs |                             |              |             |
| 0    | 5026 | 347 | Referent | Referent | Referent | Referent |
| ≥1   | 777  | 154 | 1.31 (1.06–1.61)* | 1.25 (1.02–1.54)* | 1.30 (1.05–1.60)* | 1.30 (1.06–1.60)* |
| % Attenuation of effect size for ≥1 TOD upon adjustment for arterial stiffness measure | 0.0 (referent) | 16.7 | 3.5 | 2.9 |

| No. of TODs |                             |              |             |
| 1    | 709  | 125 | 1.23 (0.99–1.53) | 1.20 (0.96–1.49) | 1.22 (0.98–1.52) | 1.22 (0.99–1.52) |
| 2    | 68   | 29  | 1.92 (1.28–2.88)† | 1.65 (1.08–2.51)* | 1.88 (1.25–2.84)* | 1.87 (1.24–2.82)* |
| P for trend | 0.002 | 0.013 | 0.003 | 0.002 |
| % Attenuation of effect size for TOD upon adjustment for arterial stiffness measure | | | | |
| 1 TOD | Referent | 12.5 | 2.3 | 2.0 |
| 2 TOD | Referent | 23.2 | 3.1 | 3.5 |

Hazard ratios (HRs) are adjusted for age, sex, body mass index, diabetes mellitus, antihypertensive treatment, smoking, total cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, lipid-lowering medications, heart rate, and estimated glomerular filtration rate. CPP indicates central pulse pressure; CVD, cardiovascular disease; MAP, mean arterial pressure; PWV, pulse wave velocity; TOD, target organ damage.

*P<0.05; †P<0.01.
Arterial Stiffness and Target Organ Damage  Vasan et al

Table 9. Relations of Arterial Stiffness to Composite Outcome of CVD Incidence or Death

| Arterial Stiffness Measure | Model Adjusted for Covariates But Not TOD | Model Adjusted for Covariates+Presence of TOD |
|---------------------------|------------------------------------------|---------------------------------------------|
|                           | HR (95% CI)                              | Value                    | HR (95% CI)                              | Value                    |
| CPP                       | 1.20 (1.10–1.30)                         | <0.0001                   | 1.18 (1.09–1.29)                         | 0.0001                   |
| % Attenuation upon adjustment for TOD | Referent                                 | 6.2%                      |                                          |                          |
| Central MAP               | 1.05 (0.96–1.16)                         | 0.30                      | 1.04 (0.94–1.15)                         | 0.45                      |
| CFPWV                     | 1.09 (0.94–1.27)                         | 0.24                      | 1.08 (0.93–1.25)                         | 0.31                      |
| No. of events/No. at risk | 501/5803                                 |                           |                                          |                          |

Hazard ratios (HRs) are per 1-SD increment in arterial stiffness measure and are adjusted for age, sex, body mass index, diabetes mellitus, antihypertensive treatment, smoking, total cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, lipid-lowering medications, heart rate, and estimated glomerular filtration rate. CFPWV indicates carotid-femoral pulse wave velocity; CPP, central pulse pressure; CVD, cardiovascular disease; MAP, mean arterial pressure; TOD, target organ damage.

typically focused on a single end organ.13–19,43–47 To our knowledge, data are limited relating vascular stiffness measures to multiple measures of TOD prospectively and elucidating the 3-way relations of these traits to incidence of CVD (Figure 1).

Our investigation establishes links between higher arterial stiffness and incident TOD in prospective analyses of individuals free of TOD at baseline. The strength of the association, presence of a dose-response, temporality of the relations, and biological plausibility are all consistent with a possible causal relationship between measures of arterial stiffness and new-onset TOD on follow-up. Furthermore, we demonstrate distinctive and synergistic associations of both presence of TOD and greater vascular stiffness with incident CVD and the composite outcome of CVD or death. These observations raise the possibility that mitigation of arterial stiffness may reduce the burden of TOD. They confirm prior reports linking TOD to CVD and are consistent with data suggesting that the monitoring and prevention of TOD may reduce the incidence of CVD.2–5

The associations of vascular stiffness with manifestations of TOD and, in turn, CVD may reflect underlying common molecular mechanisms that link microcirculatory endothelial dysfunction to increased transmission of pulsatile flow in end organs.5–11 Substantial experimental evidence links arterial stiffness to endothelial dysfunction and the presence of TOD, invoking tissue-level mechanisms of heightened inflammation and oxidative stress, and key cellular pathways (notably sirtuins, AMP kinase, m-TOR, and klotho) as reviewed elsewhere.48

Strengths and Limitations

The large community-based sample with the continuous surveillance for incidence of CVD strengthens our investigation. Three additional features of our investigation distinguish it from prior reports: (1) the comprehensive cross-sectional analyses including multiple measures of arterial stiffness and multiple measures of TOD; (2) the prospective analyses assessing the relations of multiple measures of arterial stiffness to the incidence of new-onset TOD; and (3) the longitudinal analyses relating presence of TOD to incidence of CVD and the exploration of attenuation of these relations by adjustment for arterial stiffness measures to gain insights into potential mediating influences of the latter measures on CVD.

Nonetheless, several limitations of our approach warrant acknowledgment. Select measures of TOD at baseline and follow-up were available only on subsamples, thereby constraining the overall investigation. Additionally, the observational nature of the study precludes any causal inferences and limits the ability to draw mechanistic insights into the complex relations of arterial stiffness, TOD, and CVD. We did not correct for multiple testing, which underscores the importance of replicating some of our key findings in additional samples. Last, but not the least, the Framingham cohorts are overwhelmingly white, and relations of vascular stiffness to TOD may vary with race and ethnicity.

Conclusions

Our comprehensive evaluations of a large community-based sample suggest that greater arterial stiffness is associated with a higher prevalence and incidence of TOD. We confirm the known association of TOD with incident CVD and demonstrate that the bidirectional relations of arterial stiffness and TOD may mediate, at least partially, the greater vascular risk associated with presence of TOD. Additional studies are warranted to confirm our findings in multiethnic samples and to elucidate whether lowering arterial stiffness will mitigate TOD and, in turn, lower risk for clinical CVD.

Sources of Funding

This work was supported by the National Heart, Lung, and Blood Institute’s FHS (National Institutes of Health [NIH] contracts N01-HC-25195, HHSN268201500001I and
75N92019D00031) and NIH grants HL080124, HL071039, HL077447, HL07385, 1R01HL126136, 5R01HL107385, 1R01HL60040, 1R01HL70100, R01HL131532, and R01HL134168. Dr Vasan is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine.

Disclosures
Mitchell is owner of Cardiovascular Engineering, Inc, a company that designs and manufactures devices that measure arterial stiffness. The company uses these devices in clinical trials that evaluate the effects of diseases and interventions on vascular stiffness. The remaining authors have no disclosures to report.

References
1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Riuolpe L, Zanchetti A, Kovesdi I, Krum H, Laurent S, Oparil S, Pichierri P, Rammos M, Ritz E, Rolandi M, Schmieder RE, Shi Q, Spahija L, Takeda K, Torp-Pedersen C, van Bortel L, Vranckx P, Wolski K. 2018 ESC/EAS Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
2. Devereux RB, Wachtell K, Gerber G, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B, LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2334–2349.
3. Fagard RH, Celis H, Thijs L, Zanchetti A, Kelen T, Shekhtman L, Zanchetti A, Kokkonen M, Mancia G, Verdecchia P, Weidinger F, Zoccali C, Zoccali C. 1998;113:1354–1359.
4. Gutierrez J, Eikind MS, Cheung K, Runde TL, Sacco RL, Wright CB. Pulsatile and steady components of blood pressure and subclinical cerebrovascular disease: the Northern Manhattan Study. J Hypertens. 2015;33:2115–2122.
5. Hashimoto J, Ito S. Some mechanical aspects of arterial aging: physiological mechanisms. J Appl Physiol. 2009;107:1652–1660.
6. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Cheng S, Aragam J, Levy D, Mitchell GF, Vasan RS. Mitchell GF, Vasan RS, Seshadi S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology. 2016;86:69–62.
7. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Cheng S, Aragam J, Levy D, Mitchell GF, Vasan RS. Mitchell GF, Vasan RS, Seshadi S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology. 2016;86:69–62.
8. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281–290.
9. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281–290.
10. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Cheng S, Aragam J, Levy D, Mitchell GF, Vasan RS. Mitchell GF, Vasan RS, Seshadi S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology. 2016;86:69–62.
11. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Cheng S, Aragam J, Levy D, Mitchell GF, Vasan RS. Mitchell GF, Vasan RS, Seshadi S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology. 2016;86:69–62.
12. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Cheng S, Aragam J, Levy D, Mitchell GF, Vasan RS. Mitchell GF, Vasan RS, Seshadi S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology. 2016;86:69–62.
33. DeCarli C, Massaro J, Harvey D, Hald J, Tuellberg M, Au R, Deisseroth K, D'Agostino R, Wolf PA. Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. *Neurol Aging*. 2005;26:491–510.

34. Pikula A, Beiser AS, DeCarli C, Himali JJ, Debette S, Au R, Selhub J, Tofler GH, Wang TJ, Meigs JB, Kelly-Hayes M, Kase CS, Wolf PA, Vasan RS, Seshadri S. Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. *Circulation*. 2012;125:2100–2107.

35. Kannel WB, Wolf PA, Garrison RJ. Section 34: some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements. Framingham Heart Study, 30 Year Follow-Up. *Bethesda, MD: US Department of Health and Human Services*; 1987.

36. Mitchell GF, Hwang S-J, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events. *Circulation*. 2010;121:505–511.

37. Ohyama Y, Ambale-Venkatesh B, Noda C, Kim JY, Tanami Y, Teixido-Tura G, Chugh AR, Redheuil A, Liu CY, Wu CO, Bluemke DA, Guallar E, Lima JAC. Aortic arch pulse wave velocity assessed by magnetic resonance imaging as a predictor of incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis). *Hypertension*. 2017;70:524–530.

38. Tsao CW, Lyass A, Larson MG, Levy D, Hamburg NM, Vasan RS, Mitchell GF, Vasan RS. Relation of Central Arterial Stiffness to Incident Heart Failure in the Community. *J Am Heart Assoc*. 2015;4:e002189. DOI: 10.1161/JAHA.115.002189

39. van Sloten TT, Sedaghat S, Laurent S, London GM, Pannier B, Ikram MA, Kavousi M, Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. *Circulation*. 2006;113:657–663.

40. Wu S, Chen D, Zhou C, Xiao K, Hu P, Chen W. Arterial stiffness is associated with target organ damage in subjects with pre-hypertension. *Arch Med Sci*. 2018;14:1374–1380.

41. Andrikou E, Tsiosifis C, Dimitriadis K, Chatzistamatiou V, Grassos C, Papavasiliou M, Papadopoulos D, Stefanidis C. Parallel deterioration of albuminuria, arterial stiffness and left ventricular mass in essential hypertension: integrating target organ damage. *Nephron Clin Pract*. 2011;119:c27–c34.

42. Kim ED, Tanaka H, Ballew SH, Sang Y, Heiss G, Matsushita K. Associations between kidney disease measures and regional pulse wave velocity in a large community-based cohort: the Atherosclerosis Risk in Communities (ARIC) study. *Am J Kidney Dis*. 2018;72:682–690.

43. Grabowski P, Schuijf JD, Smeets JC, van der Harst P, van der Wall EE, van der Heijden J, Rabelink TJ, van der Heijden KJ, van der Kuip DA. Arterial stiffness and risk of cardiovascular disease in the general population: the LIFE study. *J Hum Hypertens*. 2014;28:323–327.

44. Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the aging vasculature and role in age-related disease. *Circ Res*. 2018;123:825–848.